Pfizer earnings topped analysts' expectations on Tuesday, helped by demand for its cancer drugs and medicines in emerging markets.
The company not, however, signal any acquisition plans in the wake of its recent failed efforts to buy rival British drugmaker AstraZeneca.
Following the report, Pfizer's shares rose in premarket trade. (Get the latest quote here.)
The company's third-quarter earnings slipped to 57 cents per share from 58 cents a share in the year-earlier period.
Sales fell 2 percent to $12.36 billion, hurt by generic competition and expiration of a longstanding deal with Amgen Inc to co-market its Enbrel arthritis drug. But they topped Wall Street expectations of $12.24 billion.
Wall Street analysts had expected the company to post quarterly earnings of 55 cents a share on revenue of $12.24 billion.